T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR.
Sign Up to like & getrecommendations! Published in 2022 at "Cell stem cell"
DOI: 10.1016/j.stem.2022.02.002
Abstract: Fibrosis, or chronic fibroblast activation and extracellular matrix deposition, underlies most cardiovascular diseases and remains challenging to target therapeutically. Reported in Science by Rurik et al., modified mRNA technology can reprogram endogenous T cells into fibroblast-ablating CAR-Ts… read more here.
Keywords: cell immunotherapy; immunotherapy cardiac; cell; fibrosis ... See more keywords
Localized Microsphere/Hydrogel for Tumor Immunotherapy of Cardiac Glycoside with Minimal Toxicity.
Sign Up to like & getrecommendations! Published in 2022 at "ACS applied materials & interfaces"
DOI: 10.1021/acsami.2c18693
Abstract: It has been reported that cardiac glycosides (CGs) commonly used in clinical practice can inhibit tumor growth by inducing immunogenic cell death (ICD), and their positive benefits have been documented in several clinical trials of… read more here.
Keywords: localized microsphere; hydrogel tumor; tumor immunotherapy; immunotherapy cardiac ... See more keywords